v3.26.1
Segment Reporting (Tables)
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Schedule of Segment Loss and Significant Expenses

The following table is a summary of segment loss and our significant expenses (in thousands):

 

 

Three Months Ended
June 30,

 

 

Six Months Ended
June 30,

 

 

2026

 

 

2025

 

 

2026

 

 

2025

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

External R&D

 

 

 

 

 

 

 

 

 

 

 

 

ANB033

 

 

8,837

 

 

 

3,926

 

 

 

18,136

 

 

 

7,729

 

Rosnilimab

 

 

1,217

 

 

 

15,613

 

 

 

5,811

 

 

 

30,639

 

ANB101

 

 

687

 

 

 

2,040

 

 

 

2,171

 

 

 

3,521

 

ANB032

 

 

5

 

 

 

108

 

 

 

(26

)

 

 

3,644

 

Preclinical and other unallocated costs

 

 

4,451

 

 

 

4,456

 

 

 

7,747

 

 

 

8,388

 

Total External R&D(1)

 

 

15,197

 

 

 

26,143

 

 

 

33,839

 

 

 

53,921

 

Total Internal R&D(2)

 

 

10,447

 

 

 

13,129

 

 

 

25,760

 

 

 

26,816

 

Total R&D

 

 

25,644

 

 

 

39,272

 

 

 

59,599

 

 

 

80,737

 

 

 

 

 

 

 

 

 

 

 

 

 

External G&A(3)

 

 

(459

)

 

 

1,453

 

 

 

8,262

 

 

 

5,301

 

Internal G&A(2)

 

 

9,752

 

 

 

5,173

 

 

 

19,887

 

 

 

11,140

 

Total G&A

 

 

9,293

 

 

 

6,626

 

 

 

28,149

 

 

 

16,441

 

Total operating expenses

 

 

34,937

 

 

 

45,898

 

 

 

87,748

 

 

 

97,178

 

Loss from operations

 

 

(34,937

)

 

 

(45,898

)

 

 

(87,748

)

 

 

(97,178

)

 

 

 

 

 

 

 

 

 

 

 

 

Interest income

 

 

1,564

 

 

 

3,466

 

 

 

3,892

 

 

 

7,557

 

Other expense, net

 

 

(1

)

 

 

(13

)

 

 

(2

)

 

 

(20

)

Total other income, net

 

 

1,563

 

 

 

3,453

 

 

 

3,890

 

 

 

7,537

 

 

 

 

 

 

 

 

 

 

 

 

 

Segment net loss

 

$

(33,374

)

 

$

(42,445

)

 

$

(83,858

)

 

$

(89,641

)

 

(1)
External R&D consists of costs associated with our research and development activities, including drug discovery efforts, preclinical and clinical development of our programs, manufacturing, and allocated facility-related costs.
(2)
Internal R&D and G&A consist of salaries and wages, stock-based compensation, recruiting and other employee benefits.
(3)
External G&A consists of general and administrative expenses including legal services, insurance, professional fees for auditing, tax, and market research, and allocated facility-related costs not otherwise included in research and development expenses.